Department of Family Medicine, University of Virginia, Charlottesville, Virginia, USA.
Department of Family Medicine, University of Virginia, Charlottesville, Virginia, USA
BMJ Open Qual. 2023 Nov;12(4). doi: 10.1136/bmjoq-2023-002457.
Recent studies have called into question the safety of aspirin use for the primary prevention of atherosclerotic cardiovascular disease, particularly in older adults. Therefore, the objectives of this study were to (1) develop a systematic approach to identifying patients aged 70 and older taking aspirin for primary prevention, (2) provide patient and provider education about updated literature and recommendations regarding aspirin safety and (3) evaluate the impact of this intervention on aspirin de-prescribing.
This was a quality improvement intervention with prospective, longitudinal follow-up.
This study was conducted in two family medicine practices within an academic medical centre.
Patients aged 70 years and older with aspirin listed on the current medication list.
This is an electronic medical record-based chart review and educational intervention based on shared decision-making to reduce inappropriate aspirin use in primary practice. A chart review process was developed to identify the clinical indication for aspirin use. Patients taking aspirin for primary prevention were flagged for the primary care providers to review. Multilevel logistic regression models assessed factors affecting aspirin de-prescribing and longitudinal trend.
Of 361 patients aged 70 years or older, 145 (40%) were taking aspirin for primary prevention of atherosclerotic cardiovascular disease. After 9 months, aspirin was deprescribed in 42 (29%) of these patients. Patients seen by their providers during the study period had lower odds of having aspirin on their medication list (OR=0.87, 95% CI: 0.81, 0.94) as compared with patients taking aspirin who were not seen by their healthcare provider.
This is the first study to develop and implement a method of identifying potentially inappropriate aspirin use based on recent clinical evidence highlighting the risk of aspirin use for primary prevention in older adults. Future initiatives can leverage existing electronic medical record platforms to efficiently identify patients and expand these efforts to larger patient populations.
最近的研究对阿司匹林用于动脉粥样硬化性心血管疾病一级预防的安全性提出了质疑,尤其是在老年人中。因此,本研究的目的是:(1) 开发一种系统的方法来识别服用阿司匹林进行一级预防的 70 岁及以上患者;(2) 对患者和医生进行有关阿司匹林安全性的最新文献和建议的教育;(3) 评估这一干预措施对阿司匹林停药的影响。
这是一项质量改进干预措施,具有前瞻性、纵向随访。
本研究在一家学术医疗中心的两家家庭医学诊所进行。
当前药物清单上有阿司匹林的 70 岁及以上患者。
这是一项基于电子病历的图表回顾和基于共享决策的教育干预措施,旨在减少初级保健实践中不当使用阿司匹林。制定了图表审查流程,以确定阿司匹林使用的临床指征。对服用阿司匹林进行一级预防的患者进行标记,供初级保健提供者审查。多级逻辑回归模型评估了影响阿司匹林停药的因素和纵向趋势。
在 361 名 70 岁及以上的患者中,有 145 名(40%)正在服用阿司匹林预防动脉粥样硬化性心血管疾病。9 个月后,其中 42 名(29%)患者停止服用阿司匹林。与未接受医疗服务提供者治疗的服用阿司匹林的患者相比,在研究期间接受提供者治疗的患者,其药物清单上继续使用阿司匹林的可能性较低(OR=0.87,95%CI:0.81,0.94)。
这是第一项根据最近强调老年人阿司匹林一级预防风险的临床证据,开发和实施一种识别潜在不适当阿司匹林使用方法的研究。未来的举措可以利用现有的电子病历平台来有效地识别患者,并将这些努力扩展到更大的患者群体。